Salute e Benessere
Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology
This grant follows recent key milestones for Eligo, including the publication of its microbiome base-editing platform in , securing multiple foundational patents covering in situ editing of the skin microbiome, and successfully expanding its Series B funding round to $35 million . This latest non-dilutive financial support strengthens Eligo's capacity to rapidly advance its clinical pipeline.
Building on the development of its first-generation CRISPR-based topical therapeutic targeting moderate to severe acne vulgaris, Eligo will now optimize and scale up the bioproduction process of its innovative gene delivery vector ahead of later-stage clinical trials. In this endeavor, Eligo is partnering with Biose Industries, a globally recognized CDMO specializing in microbial fermentation. Biose's extensive GMP expertise in scaling complex microbial therapeutics will be instrumental in accelerating Eligo's progress toward clinical validation.
said Dr. Xavier Duportet, CEO and Co-Founder of Eligo Bioscience.
The skin microbiome plays a pivotal role in cutaneous immune regulation, and commensal bacteria residing within the hair follicle lie in immediate proximity to resident immune cells.
Eligo's unique in-situ delivery modality enables to perform in-situ genetic engineering of these commensal bacteria, turning them as localized bioreactors that can express high-potency biologics precisely where immune dysregulation occurs.
The new funding will support the exploration of multiple therapeutic payloads and the build-out of a diversified immuno-dermatology pipeline targeting chronic inflammatory and immune-mediated skin diseases with significant unmet need.
eligo.bio/france2030.
Photo: https://mma.prnewswire.com/media/2684935/Eligo_Bioscience.jpg
Logo: https://mma.prnewswire.com/media/1533529/Eligo_Bioscience_Logo.jpg
press@eligo-bioscience.com
View original content:https://www.prnewswire.co.uk/news-releases/eligo-bioscience-awarded-5-million-to-advance-breakthrough-genetic-medicine-platform-for-immuno-dermatology-302452485.html